Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 19, 2023.

Applies to cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide: oral tablet.

Serious side effects

Along with its needed effects, cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide:

Incidence not known

• Bloody urine
• bone pain
• dark urine
• decreased appetite
• decreased frequency or amount of urine
• diarrhea
• fast, shallow breathing
• general feeling of discomfort
• increased thirst
• light-colored stools
• loss of appetite
• lower back or side pain
• muscle pain or cramping
• nausea
• pain in the arms or legs
• right upper abdominal or stomach pain and fullness
• sleepiness
• stomach discomfort
• swelling of the face, fingers, or lower legs
• trouble breathing
• unusual tiredness or weakness
• vomiting
• weight gain
• yellow eyes and skin

Other side effects

Some side effects of cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Headache

For Healthcare Professionals

Applies to cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide: oral tablet.

General

In clinical trials, the most common side effects reported with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide were nausea, diarrhea, and headache. The safety profiles in patients with mild to moderate renal dysfunction and patients coinfected with HIV and hepatitis B virus were similar to safety profiles in patients with normal renal function and patients with HIV-1 monoinfection, respectively.

The most common side effects reported in clinical trials with cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate (DF) were nausea, diarrhea, upper respiratory tract infection, and depression in therapy-naive patients and nausea and fatigue in virologically-suppressed patients.

The manufacturer product information for cobicistat, elvitegravir, emtricitabine, and tenofovir DF should be consulted.^[Ref]

Genitourinary

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Common (1% to 10%): Hematuria

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Very common (10% or more): Proteinuria (up to 52%)

-Common (1% to 10%): Hematuria

Emtricitabine or tenofovir DF:

-Frequency not reported: Glycosuria

Tenofovir DF:

-Postmarketing reports: Proteinuria, polyuria^[Ref]

Hematuria (greater than 75 RBC/high power field) has been reported in up to 3% and up to 3% of patients using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and cobicistat/elvitegravir/emtricitabine/tenofovir DF, respectively. Proteinuria (all grades) has been reported in up to 52% of patients using cobicistat/elvitegravir/emtricitabine/tenofovir DF.

Glycosuria (3+ or greater) was reported with emtricitabine or tenofovir DF.^[Ref]

Gastrointestinal

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Very common (10% or more): Nausea

-Common (1% to 10%): Diarrhea, vomiting, abdominal pain, flatulence, elevated amylase, elevated lipase, dyspepsia

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Very common (10% or more): Elevated lipase (up to 17%), Nausea (up to 16%), diarrhea (up to 12%), vomiting

-Common (1% to 10%): Flatulence, elevated amylase, abdominal pain, dyspepsia, constipation

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Dyspepsia, vomiting, elevated amylase (including elevated pancreatic amylase), elevated serum lipase, abdominal distension

-Uncommon (0.1% to 1%): Pancreatitis

Tenofovir DF:

-Postmarketing reports: Abdominal pain, pancreatitis, increased amylase^[Ref]

Elevated amylase (greater than 2 times the upper limit of normal [2 x ULN]) was reported in up to 3% and up to 5% of patients using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and cobicistat/elvitegravir/emtricitabine/tenofovir DF, respectively. If serum amylase was greater than 1.5 x ULN, lipase was also measured; elevated lipase was reported in up to 5% and up to 17% of patients using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and cobicistat/elvitegravir/emtricitabine/tenofovir DF, respectively.

Dyspepsia and vomiting have been reported in at least 5% of patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.

Elevated amylase (including elevated pancreatic amylase), elevated serum lipase, abdominal distension, and pancreatitis were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.^[Ref]

Musculoskeletal

During comparison studies in therapy-naive HIV-1-infected patients, BMD decreases were greater with cobicistat/elvitegravir/emtricitabine/tenofovir DF than with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide. In virologically-suppressed tenofovir DF-treated patients who switched to cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide or who remained on initial regimen, mean BMD increased between baseline and 96 weeks in those who switched and decreased slightly in those on initial regimen; decreased BMD was also reported in patients who switched to cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide.

Elevated creatine kinase (at least 10 x ULN) has been reported in up to 11% and up to 10% of patients using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and cobicistat/elvitegravir/emtricitabine/tenofovir DF, respectively.

Arthralgia, myalgia, and back pain have been reported in at least 5% of patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.

Elevated creatine kinase, rhabdomyolysis, muscular weakness, osteomalacia (manifested as bone pain and infrequently contributing to fractures), and myopathy were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.

Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy have occurred as a result of proximal renal tubulopathy.^[Ref]

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Very common (10% or more): Decreased bone mineral density (BMD), elevated creatine kinase

-Common (1% to 10%): Osteomyelitis

-Uncommon (0.1% to 1%): Fractures (excluding fingers and toes)

-Frequency not reported: Increased biochemical markers of bone metabolism, increased BMD

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Very common (10% or more): Elevated creatine kinase

-Common (1% to 10%): Bone fractures, arthralgia

-Frequency not reported: Decreased BMD, back pain

Emtricitabine or tenofovir DF:

-Very common (10% or more): Elevated creatine kinase

-Common (1% to 10%): Arthralgia, myalgia, back pain

-Uncommon (0.1% to 1%): Rhabdomyolysis, muscular weakness

-Rare (less than 0.1%): Osteomalacia (manifested as bone pain and infrequently contributing to fractures), myopathy

Tenofovir DF:

-Frequency not reported: Decreased BMD, increased biochemical markers of bone metabolism

-Postmarketing reports: Rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures), muscular weakness, myopathy

Combination antiretroviral therapy:

-Frequency not reported: Osteonecrosis^[Ref]

Nervous system

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Common (1% to 10%): Headache, dizziness

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Very common (10% or more): Headache, dizziness

-Common (1% to 10%): Somnolence

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Paresthesia, peripheral neuropathy (including peripheral neuritis, neuropathy)^[Ref]

Paresthesia and peripheral neuropathy (including peripheral neuritis and neuropathy) have been reported in at least 5% of patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.^[Ref]

Metabolic

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Common (1% to 10%): Fluid overload, hyperkalemia

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Common (1% to 10%): Decreased appetite

Emtricitabine or tenofovir DF:

-Very common (10% or more): Hypophosphatemia

-Common (1% to 10%): Hyperglycemia, hypertriglyceridemia

-Uncommon (0.1% to 1%): Hypokalemia

-Rare (less than 0.1%): Lactic acidosis

-Frequency not reported: Altered serum glucose

Tenofovir DF:

-Postmarketing reports: Lactic acidosis, hypokalemia, hypophosphatemia

Antiretroviral therapy:

-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased glucose levels^[Ref]

Altered serum glucose (less than 40 mg/dL or greater than 250 mg/dL) has been reported in patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.

Hypophosphatemia, hyperglycemia, hypertriglyceridemia, hypokalemia, and lactic acidosis were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.

Hypokalemia and hypophosphatemia have occurred as a result of proximal renal tubulopathy.^[Ref]

Other

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Very common (10% or more): Increased fasting low-density lipoprotein (LDL) cholesterol

-Common (1% to 10%): Fatigue, increased fasting total cholesterol

-Frequency not reported: Increased high-density lipoprotein (HDL) cholesterol, increased triglycerides

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Common (1% to 10%): Fatigue, increased fasting LDL cholesterol

-Uncommon (0.1% to 1%): Elevated fasting total cholesterol, elevated fasting triglycerides, increased HDL cholesterol

Emtricitabine or tenofovir DF:

-Very common (10% or more): Asthenia

-Common (1% to 10%): Abdominal pain, fever, pain

-Frequency not reported: Elevated alkaline phosphatase, elevated fasting cholesterol, elevated fasting triglycerides

Tenofovir DF:

-Frequency not reported: Higher 1,25 vitamin D levels

-Postmarketing reports: Asthenia

Antiretroviral therapy:

-Frequency not reported: Increased weight, increased blood lipid levels^[Ref]

During trials in therapy-naive patients, increases from baseline for the fasting lipid parameters (total cholesterol, direct LDL cholesterol, and HDL cholesterol) were observed with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and cobicistat/elvitegravir/emtricitabine/tenofovir DF at 144 weeks of therapy; such increases were greater with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide.

Elevated fasting LDL cholesterol (greater than 190 mg/dL) and elevated fasting total cholesterol (greater than 300 mg/dL) have been reported in up to 11% and up to 4%, respectively, of patients using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and up to 5% and up to 3%, respectively, of patients using cobicistat/elvitegravir/emtricitabine/tenofovir DF.

In clinical trials, the following mean increases in fasting lipid values were reported after 144 weeks of therapy: total cholesterol increased by 31 mg/dL, LDL cholesterol by 20 mg/dL, HDL cholesterol by 7 mg/dL, and triglycerides by 29 mg/dL with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and total cholesterol increased by 14 mg/dL, LDL cholesterol by 8 mg/dL, HDL cholesterol by 3 mg/dL, and triglycerides by 17 mg/dL with cobicistat/elvitegravir/emtricitabine/tenofovir DF.

Elevated alkaline phosphatase (greater than 550 units/L), elevated fasting cholesterol (greater than 240 mg/dL), and elevated fasting triglycerides (greater than 750 mg/dL) have been reported in patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials. Abdominal pain, fever, and pain have been reported in at least 5% of patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.

Asthenia and pain were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.^[Ref]

Psychiatric

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Common (1% to 10%): Abnormal dreams

-Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt

-Frequency not reported: Suicidal behavior

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Common (1% to 10%): Abnormal dreams, insomnia, depression

-Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt

Elvitegravir:

-Uncommon (0.1% to 1%): Depression

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Depression, anxiety^[Ref]

Suicidal ideation, suicidal behavior, and suicide attempt were reported with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide; all were serious and occurred in patients with history of depression or psychiatric illness.

Suicidal ideation and suicide attempt were reported with cobicistat/elvitegravir/emtricitabine/tenofovir DF in patients with history of depression or psychiatric illness.

Depression was reported in clinical trials for elvitegravir with other antiretrovirals.

Depression and anxiety have been reported in at least 5% of patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.^[Ref]

Renal

In clinical trials of cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, increases in serum creatinine occurred by the second week of therapy and was stable through 144 weeks. In therapy-naive patients, the change from baseline averaged 0.04 mg/dL (3.5 mcmol/L) after 144 weeks of therapy. Increases from baseline were smaller with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide than increases with cobicistat/elvitegravir/emtricitabine/tenofovir DF at 144 weeks.

In 1 trial, 248 HIV-1-infected patients with estimated CrCl between 30 and 69 mL/min (by Cockcroft-Gault method) were treated with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide for a median duration of 144 weeks; of these patients, 65% had previously been on a stable tenofovir DF-containing regimen. This drug was permanently discontinued in 5 patients who developed renal side effects through 96 weeks; 3 of the 5 patients were among the 80 patients with baseline estimated CrCl less than 50 mL/min and 2 patients were among the 162 subjects with baseline estimated CrCl at least 50 mL/min. No further renal discontinuations occurred between 96 and 144 weeks. Overall, patients with renal dysfunction using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide in this study had a mean serum creatinine of 1.5 mg/dL at baseline and 1.4 mg/dL at 144 weeks.

In 2 trials in therapy-naive HIV-1-infected patients (median baseline estimated CrCl 115 mL/min), mean serum creatinine increased by less than 0.1 mg/dL and 0.1 mg/dL from baseline to week 144 with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and cobicistat/elvitegravir/emtricitabine/tenofovir DF, respectively. In a trial in virologically-suppressed tenofovir DF-treated patients (mean baseline estimated CrCl 112 mL/min) who switched to cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide or who remained on initial regimen, mean serum creatinine was similar to baseline for both at 96 weeks.

Elevated serum creatinine (all grades) has been reported in 10% of patients using cobicistat/elvitegravir/emtricitabine/tenofovir DF.

In clinical trials, decreases in estimated CrCl occurred early during cobicistat/elvitegravir/emtricitabine/tenofovir DF therapy. The change in eGFR averaged -14 mL/min after 144 weeks of therapy.

In a clinical trial in HIV-1-infected therapy-naive patients with mild to moderate renal dysfunction (eGFR between 50 and 89 mL/min), the change in serum creatinine and eGFR averaged 0.17 mg/dL and -6.9 mL/min, respectively, for cobicistat/elvitegravir/emtricitabine/tenofovir DF.

Acute tubular necrosis, nephritis (including acute interstitial nephritis), and nephrogenic diabetes insipidus were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.

Proximal renal tubulopathy generally resolved or improved after tenofovir DF was stopped; however, decreased CrCl did not completely resolve in some patients after stopping the drug. Rhabdomyolysis, osteomalacia, bone abnormalities (infrequently contributing to fractures), hypokalemia, muscular weakness, myopathy, and hypophosphatemia have occurred as a result of proximal renal tubulopathy.^[Ref]

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Frequency not reported: Increased serum creatinine, worsening renal dysfunction, transient acute renal failure, decreased urine protein-to-creatinine ratio (UPCR), worsening renal function

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Common (1% to 10%): Elevated serum creatinine

-Uncommon (0.1% to 1%): Renal failure, proximal renal tubulopathy, Fanconi syndrome acquired

-Frequency not reported: New onset or worsening renal impairment (including acute renal failure, Fanconi syndrome), laboratory findings consistent with proximal renal tubular dysfunction, decreased estimated CrCl, decreased estimated glomerular filtration rate (eGFR), increased UPCR

Emtricitabine or tenofovir DF:

-Rare (less than 0.1%): Acute tubular necrosis, nephritis (including acute interstitial nephritis), nephrogenic diabetes insipidus

Cobicistat:

-Frequency not reported: Increased serum creatinine, decreased estimated CrCl, tubular secretion of creatinine inhibited (renal glomerular function not affected)

Tenofovir DF:

-Postmarketing reports: Renal insufficiency, acute renal failure, renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, interstitial nephritis (including acute cases), acute tubular necrosis, nephrogenic diabetes insipidus^[Ref]

Dermatologic

Vesiculobullous rash, pustular rash, maculopapular rash, pruritus, urticaria, skin discoloration (increased pigmentation), and angioedema were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.

Skin discoloration (hyperpigmentation) was very common in pediatric patients using emtricitabine.^[Ref]

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Common (1% to 10%): Rash

-Uncommon (0.1% to 1%): Pruritus

-Postmarketing reports: Angioedema, urticaria, rash

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Very common (10% or more): Rash

-Common (1% to 10%): Rash event (includes dermatitis, drug eruption, eczema, pruritus, generalized pruritus, rash, erythematous rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, pruritic rash, urticaria)

Emtricitabine and/or tenofovir alafenamide:

-Postmarketing reports: Angioedema, urticaria

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Vesiculobullous rash, pustular rash, maculopapular rash, pruritus, urticaria, skin discoloration (increased pigmentation)

-Uncommon (0.1% to 1%): Angioedema

Emtricitabine:

-Frequency not reported: Skin discoloration (palmar-plantar hyperpigmentation)

Emtricitabine-containing products:

-Postmarketing reports: Angioedema

Tenofovir alafenamide-containing products:

-Postmarketing reports: Angioedema, urticaria

Tenofovir DF:

-Postmarketing reports: Rash^[Ref]

Hepatic

Elevated AST (greater than 5 x ULN) and elevated ALT (greater than 5 x ULN) have both been reported in up to 3% of patients using cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and up to 4% and up to 3%, respectively, of patients using cobicistat/elvitegravir/emtricitabine/tenofovir DF. Elevated ALT (greater than 3 x ULN) has been reported in up to 2% of patients using cobicistat/elvitegravir/emtricitabine/tenofovir DF.

Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 after discontinuation of emtricitabine or tenofovir DF and were associated with liver failure and liver decompensation in some emtricitabine-treated patients.

Elevated ALT (greater than 215 units/L in males and 170 units/L in females) and elevated bilirubin (greater than 2.5 x ULN) have been reported in patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.

Increased transaminases, hyperbilirubinemia, hepatic steatosis, and hepatitis were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.^[Ref]

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Common (1% to 10%): Elevated AST, elevated ALT

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Common (1% to 10%): Elevated AST, elevated ALT

Emtricitabine:

-Frequency not reported: Liver failure, liver decompensation

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Increased transaminases, hyperbilirubinemia

-Rare (less than 0.1%): Hepatic steatosis, hepatitis

-Frequency not reported: Severe acute exacerbations of hepatitis B, elevated ALT, elevated bilirubin

Tenofovir DF:

-Frequency not reported: Severe hepatomegaly with steatosis

-Postmarketing reports: Increased liver enzymes (primarily AST, ALT, GGT), hepatic steatosis, hepatitis^[Ref]

Respiratory

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide:

-Very common (10% or more): Pneumonia (up to 13%)

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Common (1% to 10%): Upper respiratory tract infection, bronchitis

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, increased cough, rhinitis

Tenofovir DF:

-Postmarketing reports: Dyspnea^[Ref]

Nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, increased cough, and rhinitis have been reported in at least 5% of patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.^[Ref]

Ocular

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Uncommon (0.1% to 1%): Ocular icterus^[Ref]

Immunologic

Cobicistat/elvitegravir/emtricitabine/tenofovir DF:

-Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)

Emtricitabine and/or tenofovir alafenamide:

-Postmarketing reports: Autoimmune hepatitis

Emtricitabine:

-Postmarketing reports: Immune reconstitution syndrome

Tenofovir DF:

-Postmarketing reports: Immune reconstitution syndrome^[Ref]

Hematologic

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Neutropenia

-Uncommon (0.1% to 1%): Anemia

-Frequency not reported: Decreased neutrophils^[Ref]

Decreased neutrophils (less than 750/mm3) have been reported in patients receiving emtricitabine or tenofovir DF with other antiretroviral drugs in other clinical trials.

Neutropenia and anemia were reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.

Anemia was common in pediatric patients using emtricitabine.^[Ref]

Hypersensitivity

Emtricitabine or tenofovir DF:

-Common (1% to 10%): Allergic reaction

Tenofovir DF:

-Postmarketing reports: Allergic reaction (including angioedema)^[Ref]

Allergic reaction was reported in clinical trials or during postmarketing experience for emtricitabine or tenofovir DF with other antiretrovirals.^[Ref]

Endocrine

Tenofovir DF:

-Frequency not reported: Higher serum parathyroid hormone levels

Frequently asked questions

• Is Genvoya used for PrEP?
• Is Genvoya better than Stribild?
• Genvoya vs Stribild for HIV - How do they compare?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer